Skip to main content
OpenTrials
Completed

NCT Number: NCT04962919

Survival Outcomes in Metastatic Prostate Cancer in the Brazilian Population - Analysis of Individual Characteristics and Treatment Modalities in Different National Health Institutions.

Survival outcomes in metastatic prostate cancer in the population Brazilian - analysis of individual characteristics and modalities of treatment in different national health institutions

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Prostatic Neoplasms, Castration-Resistant Genital Diseases Genital Diseases, Male Genital Neoplasms, Male Male Urogenital Diseases Neoplasms Neoplasms by Site Prostatic Diseases Prostatic Neoplasms Urogenital Diseases Urogenital Neoplasms

Age range

18 year and older

Sex eligibility

Male

Study type

Observational

Primary location

Ética Pesquisa Clínica, Salvador, Estado de Bahia, Brazil

Loading trial locations.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Diagnosis of castration-resistant metastatic prostate cancer diagnosed in the period between January 2014 and December 2017.

Exclusion criteria

  • Diagnosis of localized or locally advanced or metastatic disease sensitive to castration;
  • Patients with medical records filled with incomplete data that make it impossible to evaluate the treatment received.

Treatment and study plan

Primary outcomes

  1. Describe cause-specific survival in patients with castration-resistant prostate cancer in different institutions in Brazil.

    Time frame: December of 2017

Secondary outcomes

  1. To describe the sociodemographic characteristics of patients with castration-resistant metastatic prostate cancer in Brazil;

    Time frame: December of 2017

  2. To describe comorbidities of patients with castration-resistant metastatic prostate cancer in Brazil;

    Time frame: December of 2017

  3. To describe the clinicopathological characteristics of patients with metastatic castration-resistant prostate cancer in Brazil;

    Time frame: December of 2017

  4. To compare overall survival among patients with castration-resistant metastatic prostate cancer treated in the SUS and in the private network;

    Time frame: December of 2017

  5. To compare the treatments performed by patients with castration-resistant metastatic prostate cancer in the SUS and in the private network;

    Time frame: December of 2017

  6. To describe the rates of skeletal-related complications

    Time frame: December of 2017

  7. To describe the rate of admissions

    Time frame: December of 2017

  8. To describe the number of lines of treatment that patients have undergone

    Time frame: December of 2017

  9. To describe the presence or absence of treatments bone-directed

    Time frame: December of 2017

Sponsors and collaborators

Lead sponsor

Latin American Cooperative Oncology Group

Other

Registry information

Acronym: LACOG 1818

Important dates

Study start
2020
Primary completion
2024
Study completion
2024
First posted
Jul 15, 2021
Registry last updated
Sep 2, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.